Shares of NRX Pharmaceuticals cratered 23.2% to $3.55 in pre-market trading on June 3, 2026, after the company disclosed plans for an underwritten public offering of common stock — a move that immediately spooked investors worried about their stakes being watered down. NRX Pharmaceuticals Sells New Shares to Stay Alive — But Can a Cash-Strapped Biotech Afford to Dilute Investors Who Just Watched the Stock Double?
Shares plunged 23% to $3.55 overnight after NRx Pharmaceuticals, a tiny clinical-stage biotech developing ketamine-based treatments for suicidal depression, announced a new stock offering that could flood the market with additional shares and shrink the value of every existing investor's stake. The move underscores a brutal reality: the company is running dangerously low on cash and has no approved drugs generating meaningful revenue.
The Company Needs Money Just to Keep the Lights On
NRx ended Q1 2026 with just $6.7 million in cash, a $17.8 million working-capital deficit, and management itself flagged "substantial doubt" about its ability to continue operating.
Operating losses widened to $4.74 million in the quarter while cash used in operations hit $4.3 million — meaning the company was burning through its reserves in roughly a quarter and a half. After quarter-end, NRx raised about $7 million through an existing stock-sale program, but that was clearly not enough.
This Isn't the First Time Shareholders Have Been Diluted
Just four months ago, NRx launched a separate $20 million at-the-market stock program through H.C. Wainwright. Now the company is layering on another offering, this time an underwritten deal led by BTIG as lead bookrunner with Lucid Capital Markets as joint manager.
The underwriter also gets a 30-day option to buy an extra 15% of shares sold. Exact pricing hasn't been set, but each round of new shares cuts deeper into existing ownership.
The Stock Had Been on a Run — Raising the Stakes NRXP traded as low as $1.62 over the past year before rallying to $4.62 by June 2 — a nearly threefold surge fueled by a string of FDA milestones. The company's preservative-free ketamine received Fast Track status, and its oral follow-on pill earned Breakthrough Therapy designation — both for suicidal depression. A key FDA review date for the generic ketamine product is July 29, 2026. The offering's timing suggests management may be racing to stockpile cash before that verdict.
Where the Proceeds Go Remains Vague
NRx says it has "broad discretion" over the money, earmarking it loosely for working capital, growth, or acquisitions — with no specific allocation disclosed. For a company with just 29 employees and trailing revenue of only $1.2 million, that ambiguity gives shareholders little comfort. The question now: will a July FDA catalyst arrive fast enough to justify the pain?